To The Moon

$UnitedHealth(UNH)$  sharing is caring

📈 UNH Breakout: Buffett’s Healthcare Bet — $400 Next? UnitedHealth ($UnitedHealth(UNH)$  $UnitedHealth(UNH)$  ) just smashed through its $320 resistance, and the momentum is catching fire. After reaffirming its 2025 earnings outlook — with EPS projected at $16.00+ and revenue guided at $445.5B–$448B — Wall Street is getting even bolder. Consensus estimates sit slightly higher, with $16.24 EPS on ~$448.2B revenue. The stock’s rally has reignited the debate: is UNH a defensive giant quietly transforming into a growth story, or is this the moment to lock in profits before the climb stalls? Add in the fact that Warren Buffett loaded up $1.6B at an average $314 — and the story gets even juici

Find out more here:Cash Boost Lucky Draw Hey friend! Tap to help me out and get a mystery gift for yourself—check it out now!

$UnitedHealth(UNH)$ 💊📈🛡️ $UNH Breakout With Value Compounding 💊📈🛡️ I see UnitedHealth breaking out as a value compounder hiding in plain sight. Despite people served falling (–4.08% YoY), Optum Health growth offsets declines, driving superior cash returns. At just 15.2x P/E and a 7.92% FCF yield, the setup is compelling. Breakout over $350 now sets short-term target $370 and medium-term path toward $395–400. Support holds at $345–347, and history shows UNH breakouts of this structure deliver 12–15% measured moves. Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀

$UnitedHealth(UNH)$   Support for a move toward $400: 1. Strong fundamentals: UnitedHealth has diversified business (healthcare plans + services, via Optum etc.), strong cash flow, and decent earnings growth. Those help build a base for higher valuations.  2. Recent upgrades and raised targets: Some upgrades (like at Truist) show increasing confidence. These tend to help with investor sentiment.  3. Room for multiple expansion: If UNH can demonstrate margin improvement, reduce regulatory risk, or show accelerating growth, the market may reward it with a higher P/E, pushing the price up. Challenges / what needs to go right / risk factors: • Regulatory risk is nontrivial for big health insurers. Changes in Medicare/Medicaid policy, reimbu

UnitedHealth Group is a stock in need of a second opinion. Trading at $353, down more than 40 per cent from its 52-week high, it sits at a valuation multiple of just 15 times earnings — modest for a company that still pulls in over $420 billion in annual revenue. The market is clearly pricing in lasting damage. I think the case is more nuanced. If Optum can recover margins, if Medicare Advantage scrutiny is contained, and if capital returns are deployed with conviction, then the climb back to $400 is achievable. Networks align: Optum’s reach could redraw healthcare’s balance sheet Optum’s margin pulse Optum has become the engine that keeps $UnitedHealth(UNH)$ competitive. It now accounts for nearly half of operating earnings, yet recent quarters ha

$UnitedHealth(UNH)$  yes will definitely reach $400

UnitedHealth continues to jump after the health insurer reaffirmed its full-year 2025 earnings outlook.The company said it continues to expect adjusted earnings of at least $16.00 per share with revenue in the range of $445.5 billion to $448.0 billion. Wall Street currently forecasts earnings of $16.24 per share on revenue near $448.2 billion.After breaking the key resistance level of $320, is UNH hitting the short term peak?Have you jumped on the wagon with Buffett?🎁Special Notes: Whoever showed up on the” What the Tigers Say” column will receive 100 Tiger Coins and an exclusive interview invitation to honor your contribution.Click titles to read the full analysis:1. @TwoDeMoon:Key Points:This is a defensive and fundamental / value pi

$联合健康(UNH)$   I would like to say: "Thanks        Warren  Buffett!"

$UnitedHealth(UNH)$  this is a defensive and fundamental / value pick. For those who bought at 300 or below, congrats! Still lots of runway to go!!! $400 price target before end 2026

$UnitedHealth(UNH)$ UnitedHealth Group (UNH) shares surged after reaffirming its 2025 earnings outlook of at least $16 per share on revenue of $445.5-$448 billion, slightly below Wall Street's $16.24 EPS and $448.2 billion forecast, but signaling confidence amid healthcare challenges. The stock, a Buffett favorite through Berkshire Hathaway's 1.1 million share stake, trades at $320.25, up 8.76% recently, with analysts maintaining a Buy rating and $387.63 average target. With the S&P 500 at 6,520, Nasdaq at 21,950, and Bitcoin at $123,456, the VIX at 14.12 reflects calm amid oil at $74.50/barrel. Posts found on X buzz with "UNH rebound" optimism, but tariff fears linger. This deep dive explores the reaffirmation, current stance, future prospects

$UnitedHealth(UNH)$   UnitedHealth (UNH) Current Situation Guidance reaffirmed: Management reiterated ≥ $16.00 EPS and $445.5B–$448B revenue for FY2025. This is broadly in line with Wall Street’s expectations, signalling stability. Market reaction: Shares broke through the $320 resistance level, which had been a ceiling for months. Technical traders view this as a bullish breakout. Valuation context: At ~$320, UNH trades around 20x forward earnings—not cheap, but reasonable for a defensive healthcare leader with consistent growth. --- Short-Term View Breakout risk: After a strong run, stocks often pause or consolidate as early buyers take profits. Catalysts ahead: Medicare Advantage enrolments, medical cost trend

$UnitedHealth(UNH)$ $UnitedHealth(UNH)$   📈 UNH Breakout: Buffett’s Healthcare Bet Roars Past $320 — Buy or Bail? UnitedHealth Group (UNH) has smashed through the $320 resistance level, sending a clear signal to Wall Street: healthcare’s quiet giant isn’t done yet. With a reaffirmed 2025 outlook of $16+ EPS and revenue guidance of $445B–$448B, the numbers are steady. Wall Street’s consensus is even bolder, penciling in $16.24 EPS on ~$448.2B revenue. But here’s what’s really fueling excitement: Warren Buffett’s $1.6B stake. When the Oracle of Omaha places a billion-dollar bet, retail investors notice. UNH suddenly looks less like a slow-moving insurer and more like a

$UnitedHealth(UNH)$ $Alibaba(BABA)$ $SPDR S&P 500 ETF Trust(SPY)$ I’m fully convinced $UNH is setting up for one of the most asymmetric upside trades of the year. With Berkshire’s stake anchoring conviction, Congressional buys lighting the fuse, shorts overloaded, and fundamentals stabilizing, this looks less like a recovery and more like a full-scale rerating. 🧮 Discounted Cashflow Conviction I’ve run the DCF, and the result is decisive. Equity value per share comes in at $580.03, nearly 70% upside from here. Present value of the next decade of cashflows plus terminal value makes the current market price deeply disconnected from intrinsic worth. At an 8.5% dis

“Markets gave their best shot with Tech — but valuations stretched and momentum cooled. Now, capital is rotating into Healthcare, with defensives like UnitedHealth leading the narrative. The expected story finally plays out:$UnitedHealth(UNH)$  

Healthcare’s setting up clean, UNH holding $318 feels like the trigger that’ll drive the wedge breakout you mapped on CURE. I’m seeing the same sector energy that tech had in July, and it’s wild to think a defensive space could push momentum like this 📈

1. $Oscar Health, Inc.(OSCR)$ Still holding and breakout looks strong. Resistance at $20–$21 is where you could trim profits. If price clears $20–$23, a level rejected 4 times before, we could see a 6-month rally toward $40. I’ll likely take partial profits but keep 50% in case it runs.Image2. $UnitedHealth(UNH)$ Smart money zone held to perfection 🟣Break above $320 opens the door for a move back into the $360–$400 range. Saving some capital in case price pulls back $280 one last time.Image3. $Robinhood(HOOD)$ HOOD — I was dead wrong on this one 😑But even now, I still don’t see it as a buy. You’re paying a massive premium.Some calls age like 🍷... others like 🥛Imag

$UnitedHealth(UNH)$  

$UNH 20250919 290.0 PUT$ UNH getting bullish, selling a put for premium

$UnitedHealth(UNH)$ $Direxion Daily Healthcare Bull 3X Shares(CURE)$ I’m fully convinced this move in UnitedHealth ($UNH) isn’t just noise; it’s the ignition point that could reshape healthcare momentum across both single-stock and leveraged ETF structures. 💡 UnitedHealth Inverse Head & Shoulders (Micro Frame) This morning’s price action confirmed the bullish IHS breakout with $318 now acting as the inflection pivot. As long as that level holds, the setup points toward $325–$330. Options flow backs it up: calls are leading with a 0.28 put/call ratio, IV30 elevated to 34.33, and expected daily swings near $6.90. The skew flattening signals traders aren’t hedging downside, they’re leaning into upside con

📈 UNH Breakout: Buffett’s Healthcare Bet — $400 Next? UnitedHealth ($UnitedHealth(UNH)$  $UnitedHealth(UNH)$  ) just smashed through its $320 resistance, and the momentum is catching fire. After reaffirming its 2025 earnings outlook — with EPS projected at $16.00+ and revenue guided at $445.5B–$448B — Wall Street is getting even bolder. Consensus estimates sit slightly higher, with $16.24 EPS on ~$448.2B revenue. The stock’s rally has reignited the debate: is UNH a defensive giant quietly transforming into a growth story, or is this the moment to lock in profits before the climb stalls? Add in the fact that Warren Buffett loaded up $1.6B at an average $314 — and the story gets even juici

$UnitedHealth(UNH)$ $Alibaba(BABA)$ $SPDR S&P 500 ETF Trust(SPY)$ I’m fully convinced $UNH is setting up for one of the most asymmetric upside trades of the year. With Berkshire’s stake anchoring conviction, Congressional buys lighting the fuse, shorts overloaded, and fundamentals stabilizing, this looks less like a recovery and more like a full-scale rerating. 🧮 Discounted Cashflow Conviction I’ve run the DCF, and the result is decisive. Equity value per share comes in at $580.03, nearly 70% upside from here. Present value of the next decade of cashflows plus terminal value makes the current market price deeply disconnected from intrinsic worth. At an 8.5% dis

UnitedHealth continues to jump after the health insurer reaffirmed its full-year 2025 earnings outlook.The company said it continues to expect adjusted earnings of at least $16.00 per share with revenue in the range of $445.5 billion to $448.0 billion. Wall Street currently forecasts earnings of $16.24 per share on revenue near $448.2 billion.After breaking the key resistance level of $320, is UNH hitting the short term peak?Have you jumped on the wagon with Buffett?🎁Special Notes: Whoever showed up on the” What the Tigers Say” column will receive 100 Tiger Coins and an exclusive interview invitation to honor your contribution.Click titles to read the full analysis:1. @TwoDeMoon:Key Points:This is a defensive and fundamental / value pi

$UnitedHealth(UNH)$ $UnitedHealth(UNH)$   📈 UNH Breakout: Buffett’s Healthcare Bet Roars Past $320 — Buy or Bail? UnitedHealth Group (UNH) has smashed through the $320 resistance level, sending a clear signal to Wall Street: healthcare’s quiet giant isn’t done yet. With a reaffirmed 2025 outlook of $16+ EPS and revenue guidance of $445B–$448B, the numbers are steady. Wall Street’s consensus is even bolder, penciling in $16.24 EPS on ~$448.2B revenue. But here’s what’s really fueling excitement: Warren Buffett’s $1.6B stake. When the Oracle of Omaha places a billion-dollar bet, retail investors notice. UNH suddenly looks less like a slow-moving insurer and more like a

$UnitedHealth(UNH)$ UnitedHealth Group (UNH) shares surged after reaffirming its 2025 earnings outlook of at least $16 per share on revenue of $445.5-$448 billion, slightly below Wall Street's $16.24 EPS and $448.2 billion forecast, but signaling confidence amid healthcare challenges. The stock, a Buffett favorite through Berkshire Hathaway's 1.1 million share stake, trades at $320.25, up 8.76% recently, with analysts maintaining a Buy rating and $387.63 average target. With the S&P 500 at 6,520, Nasdaq at 21,950, and Bitcoin at $123,456, the VIX at 14.12 reflects calm amid oil at $74.50/barrel. Posts found on X buzz with "UNH rebound" optimism, but tariff fears linger. This deep dive explores the reaffirmation, current stance, future prospects

UnitedHealth Group is a stock in need of a second opinion. Trading at $353, down more than 40 per cent from its 52-week high, it sits at a valuation multiple of just 15 times earnings — modest for a company that still pulls in over $420 billion in annual revenue. The market is clearly pricing in lasting damage. I think the case is more nuanced. If Optum can recover margins, if Medicare Advantage scrutiny is contained, and if capital returns are deployed with conviction, then the climb back to $400 is achievable. Networks align: Optum’s reach could redraw healthcare’s balance sheet Optum’s margin pulse Optum has become the engine that keeps $UnitedHealth(UNH)$ competitive. It now accounts for nearly half of operating earnings, yet recent quarters ha

$UnitedHealth(UNH)$ $Direxion Daily Healthcare Bull 3X Shares(CURE)$ I’m fully convinced this move in UnitedHealth ($UNH) isn’t just noise; it’s the ignition point that could reshape healthcare momentum across both single-stock and leveraged ETF structures. 💡 UnitedHealth Inverse Head & Shoulders (Micro Frame) This morning’s price action confirmed the bullish IHS breakout with $318 now acting as the inflection pivot. As long as that level holds, the setup points toward $325–$330. Options flow backs it up: calls are leading with a 0.28 put/call ratio, IV30 elevated to 34.33, and expected daily swings near $6.90. The skew flattening signals traders aren’t hedging downside, they’re leaning into upside con

It’s not just Warren Buffett—top global quant fund Renaissance Technologies, David Tepper’s Appaloosa Management, and legendary investor Michael Burry have all taken positions in UnitedHealth Group (UNH). This convergence of heavyweights signals strong institutional confidence, even as short-term regulatory and cost pressures linger. With the stock’s valuation currently at historic lows, investors are starting to wonder: could this be the perfect entry point? UnitedHealth (UNH) A Closer Look at UnitedHealth Group UnitedHealth Group isn’t your average health insurer—it’s a sprawling, diversified healthcare empire. The company operates through four core segments: UnitedHealthcare – Provides health benefit plans and services to individuals, small and large businesses, public sector employers,

$UnitedHealth(UNH)$ $Regeneron Pharmaceuticals(REGN)$ $Meta Platforms, Inc.(META)$💎 I’m calling this the most coordinated institutional strike on a Dow component this year, with Buffett, Burry, and Tepper all betting on a V-shaped recovery from multi-year lows. Institutional Endorsement Sparks Double-Digit After-Hours Surge I’m leaning into UnitedHealth here because the tape just flipped from distress to endorsement; Berkshire Hathaway disclosed a new 5.04 million-share stake worth about $1.57 billion and UNH ripped roughly 12 percent after-hours to $300.50 on 14Aug25 (SEC, MarketWatch, 14Aug25). Scion Asset Management revealed $190 million in UNH call options plu

$UnitedHealth(UNH)$   Buffett Drops $1.6B on UnitedHealth — Are You Buying at $300? 🚀📊 When Warren Buffett moves, markets pay attention. In Berkshire Hathaway’s latest Q2 2025 13F, the Oracle of Omaha revealed a $1.6 billion stake in UnitedHealth Group (UNH) — buying in at an average of $314 per share. Today, UNH trades below Buffett’s cost at ~$300. 👉 The rare question for retail investors: Do you buy with Buffett… or wait for a deeper pullback? --- Why UNH Could Be Buffett’s Quiet Power Play 💡 Buffett has dipped into healthcare before — but this is the #1 US health insurer, serving 50M+ members and dominating Medicare Advantage. Why now? 📉 Valuation reset: Down from $550 in 2022 to ~$300 after policy fears 🛡 De

$UnitedHealth(UNH)$ $Centene(CNC)$ $Molina Healthcare(MOH)$ I’m tracking one of the most asymmetric setups in years as Buffett’s $1.6B UNH buy ignites CNC and MOH, Medicaid policy shifts add fuel, and hedge fund flows collide with a $1.2M bearish bet, setting the stage for a sector-wide repricing that could move fast. From Deep Value to Breakout: Medicaid Giant Reclaims Momentum I’m seeing CNC surge 6.02% to $28.55, breaking above its 20-day MA with volume support after weeks of accumulation. Medicaid exposure is the highest in the sector at 45.8% of its total medical book, with 12.8m lives covered. A 100 bps margin compression in Medicaid would hit EPS by 66.2%, ye

1. The Trend in Berkshire Hathaway's 13F Filing: Cashing in on Technology at a High Level, and Shifting to a Left-Side Position in Industrials, Real Estate, and UtilitiesAfter the market closed on August 14, 2025, $Berkshire Hathaway(BRK.B)$ $Berkshire Hathaway(BRK.A)$ filed its 13F report, which shows:Divestments: $Apple(AAPL)$ by 20 million shares (-6.7%), $Bank of America(BAC)$ by 26.3 million shares (-4.2%);Liquidations: $T-Mobile US(TMUS)$New Entries/Increases: $UnitedHealth(UNH)$ by 5.04 million shares, a small increase in

$UnitedHealth(UNH)$ led the decline of 15 high-quality $Dow Jones(.DJI)$ components with a market capitalization over $100 billion.Do you own any oversold high-quality stocks?📈 Check out TigerAI's analysis.I. $UnitedHealth(UNH)$ declined almost 8 % on Tuesday after releasing earnings.Key facts of $UnitedHealth(UNH)$• Reported 29-Jul-2025 pre-market; stock closed –7.9 %.• Options volume ranked #5 across all US names that day.• YTD 2025 (to 29 Jul) UNH is –48.39 %, the steepest drop among US mega-caps (≥ 100 bn USD).• Tiger Trade “Top Bought” leaderboard: UNH has been the #2 most-bought stock over the last 20-, 10-, 5-, 3- an

UnitedHealth Group ( $UnitedHealth(UNH)$ ) faced a rough start to the week, tumbling 5% in premarket trading after its Q2 2025 earnings report on July 29, 2025, missed earnings per share (EPS) expectations and offered a disappointing profit outlook. The health insurance giant reported a Q2 EPS of $4.08, falling short of the consensus forecast of $4.45, while revenue of $111.62 billion slightly exceeded the $111.59 billion expected. With the stock now hovering around $266.10 after the drop, investors are eyeing a potential dip to $250—a level not seen since earlier this year. Is this a golden opportunity to buy a healthcare leader at a discount, or a risky bet amid ongoing challenges? This report dives into UNH’s earnings, the reasons behind the mis

$UnitedHealth(UNH)$ UnitedHealth Group (NYSE: UNH) saw its shares drop over 5% following its second-quarter earnings release, bringing the stock down to approximately $268 per share. Year-to-date, the stock has plummeted 46.8%, and over the past 12 months, it’s lost more than half its value. From a 52-week high of $630.73, UNH now trades much closer to its 52-week low of $248.88, set earlier in April. A Mixed Quarter with Troubling Forward Guidance Q2 results presented a mixed picture. Non-GAAP EPS came in at $4.08, missing consensus estimates by $0.37. Revenue was reported at $111.62 billion—up 12.9% year-over-year and in line with expectations. However, what truly rattled investors was the company’s full-year 2025 guidance. Management now expects

$UnitedHealth(UNH)$ Wall Street’s biggest names are betting big on UnitedHealth Group (UNH), with Warren Buffett’s Berkshire Hathaway leading the charge alongside Renaissance Technologies, David Tepper’s Appaloosa Management, and Michael Burry’s Scion Asset Management. As of August 19, 2025, UNH closed at $308.49, a stunning 11.98% jump in 24 hours, fueled by these heavyweight investments. With the S&P 500 at 6,466.58, Bitcoin at $124,002, and oil at $75/barrel amid 30-35% tariffs, the rally stands out, though the VIX at 14.49 suggests calm waters—or a brewing storm. Trading at a P/E of 12, near a decade-low valuation, UNH’s plunge from $630.73 to $234.60 over the past year has sparked a buying frenzy. Can it close above $200 this week, or is t

$UnitedHealth(UNH)$ Warren Buffett’s Berkshire Hathaway dropped a bombshell with its Q2 2025 13F filing today, August 15, 2025, unveiling a bold new stake in UnitedHealth Group (UNH). The investment giant snapped up 5.039 million shares of the U.S. health insurance titan for approximately $1.6 billion, with an average purchase price of $314 per share. By quarter’s end, the position was valued at $1.57 billion, securing its spot as the 18th largest holding in Berkshire’s $300 billion portfolio, trailing Amazon and Constellation Brands (STZ). With the S&P 500 at 6,466.58, Nasdaq at 21,713.14, and Bitcoin surging to $124,002, the market pulses with optimism, though tariffs (30% on EU/Mexico, 35% on Canada) and oil at $75/barrel cast shadows. Is th

🌟🌟🌟What is a Cigar Butt Strategy?  In his early years, Warren Buffett embraced a gritty form of value investing known as the  "Cigar Butt Strategy ".  Inspired by Benjamin Graham, it involved buying companies so cheap that they were practically discarded, yet still had "one last puff" of value left. "A cigar butt found on the street that has only one puff left in it, may not offer much of a smoke but the bargain purchase will make that puff all profit" said Warren Buffett in his 1989 Shareholder Letter. Warren Buffett would buy distressed companies trading below their liquidation value, extract a small gain, maybe a dividend or perhaps a turnaround and move on.  It was rational, disciplined and profitable but it lacked soul.  Why The Cigar Butt Strategy Worked and

$Novo-Nordisk A/S(NVO)$ was scheduled to report Q2 earnings on Aug. 6, but chose to issue an early earnings warning.There has also been a change of CEO, with Maziar Mike Doustda replacing Lars Fruergaard Jørgensen on August 7th.Earnings warning and market reactionSales & Profit Adjustments: Full year 2025 sales growth estimate is lowered to 8%-14% (CER ) from 13%-21% (CER) and operating profit growth is lowered to 10%-16% (CER) from 16%-24%, which is significantly lower than analysts' expectations of 16.6%. In Danish krone terms, sales and profit growth fell by a further 4% and 7% respectively, mainly due to the depreciation of the US dollar.The core driver of the downgrade stems from Wegovy, with lower-than-expected penetration in the out-of-p

$Berkshire Bancorp, Inc.(BERK)$ $UnitedHealth(UNH)$ Warren Buffett, often hailed as the Oracle of Omaha, has once again captured the attention of the investing world. In a move that sent shockwaves through Wall Street, Berkshire Hathaway disclosed a $1.6 billion investment in UnitedHealth Group (NYSE: UNH), acquiring more than 5 million shares. This represents Buffett's first foray into the healthcare sector since 2010, signaling renewed confidence in an industry that is both essential and complex. The timing of this investment is particularly significant. UNH’s stock has traded near $300 amid broader market volatility and sector-specific challenges. For investors, Buffett’s stake raises compelling questio